Cargando…

Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic

Detalles Bibliográficos
Autores principales:	Das, Ashis K., Chang, Eunice, Paydar, Caleb, Broder, Michael S., Orroth, Kate K., Cordey, Myriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442299/ https://www.ncbi.nlm.nih.gov/pubmed/37482565 http://dx.doi.org/10.1007/s13555-023-00984-2

Ejemplares similares

Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic
por: Das, Ashis K., et al.
Publicado: (2023)

Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink
por: Persson, Rebecca, et al.
Publicado: (2022)

Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database
por: Husni, M Elaine, et al.
Publicado: (2022)

Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
por: Palfreeman, Andrew C, et al.
Publicado: (2013)

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
por: Cetkovská, Petra, et al.
Publicado: (2023)

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study
por: Jonak, Constanze, et al.
Publicado: (2023)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Clinical potential of apremilast in the treatment of psoriatic arthritis
por: Cauli, Alberto, et al.
Publicado: (2014)

Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis
por: Gao, Jia C, et al.
Publicado: (2022)

Apremilast or Methotrexate: The Arrows in the Quiver for Psoriasis
por: Panda, Gautam, et al.
Publicado: (2023)

Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study
por: Klein, Toni Maria, et al.
Publicado: (2021)

Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2020)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
por: Jeon, Caleb, et al.
Publicado: (2017)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Recurrent generalized pustular psoriasis possibly triggered by apremilast
por: Wang, Wen-Ming, et al.
Publicado: (2020)

A case of erythrodermic psoriasis successfully treated with apremilast
por: Megna, Matteo, et al.
Publicado: (2021)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
por: Murage, Mwangi J, et al.
Publicado: (2018)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

Successful treatment with secukinumab in an HIV‐positive psoriatic patient after failure of apremilast
por: Romita, Paolo, et al.
Publicado: (2022)

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule
por: Afra, T. P., et al.
Publicado: (2019)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan, Murlidhar, et al.
Publicado: (2021)

Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019)

Combining secukinumab and apremilast to successfully treat refractory psoriatic skin and joint disease: A novel approach
por: Nisar, Muhammad K.
Publicado: (2019)

Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis
por: Spencer, Riley K., et al.
Publicado: (2023)

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
por: Mease, Philip J., et al.
Publicado: (2023)

Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Apremilast Coadministered with Secukinumab for Safe and Effective Control of Psoriasis with Resultant Reduction of Maintenance Dose of the Biologic
por: De, Abhishek, et al.
Publicado: (2019)

Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report
por: Shah, Bela J, et al.
Publicado: (2019)

Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
por: Tanaka, Masayuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_43e8i7nkv9sau2srapch0cs087